Dr Andrew M. Bartkowski, M.D., M.Sc., MBA,
over the past 20 years participated in few biotechnology projects in the USA; Fibrin Technologies Co.& DuPont Corp.-JV on new generation of tissue glue/ sealants, clinical evaluation, applications in humans and production, R&D -JV with VA-US-Administration & US Government special programme, together with Professor Dr. John F. Lontz, international expert on biophysics and biomaterials like PDM -Siloxane and its clinical applications in wounded soldiers, maxillofacial epitheses and its clinical applications, R&D-JV on transgenic animals and allografts and its clinical applications.
Prof. Dr hab. Marek Godlewski, Institute of Physics IF PAN
specialist in the field of production and optimisation of nanoparticles by hydrothermal method, specialist in the field of solid state physics, fluorescence and luminescence of nanostructures, several hundred publications and several thousand citations, over 50 medals and prises on the international innovation fairs.
Ralph Dittman
Professor Dr. M.D.,MPH, MCSE, Dittman & Associates Group
Expert in medicine, biotechnology, graduate of both Harvard University and Stanford University, with degrees in medicine and electronics, researcher affiliated with Harvard Medical School, interested in new biotech approach to treat degenerative diseases like Parkinson, Alzheimer, Becks, SM etc. Professor Ralph Dittman has been actively cooperating with many entities involved in the stem cell research, funded his own private laboratory and has also been cooperating actively with Dr.Bartkowski and the BMSG Inc. in many innovative projects.
Zbigniew Dabczewski
Ph.D.,Emeritius Professor of Genetics and Veterinary Medicine.
One of the co-founders of BMSG and, at the same time, one of the very few pioneers of medical and veterinary genetics in Poland. Over the period of twenty years, he was working as a professional consultant at the United Nations in more than twenty different countries worldwide. Recognized as expert at the BESO-British Executives Service Overseas. He used to work as a consultant for different governments. Serves as a Honorary CEO at BMSG.
Wlod. Maslinski
PhD, Professor of Medicine.
Head, Department of Immunology at the Institute of Rheumatology in Warsaw, Poland. Recognized expert on clinical immunology. In the USA, he worked at the Beth Israel Deaconess Medical Center, Harvard Medical School, between 1989-1997. He is currently at the Institute of Rheumatology in Warsaw. The major focus of his work has been on Interleukins ( IL-15) and biomaterials used in clinical medicine. Together with Prof.T.Wierzchon, he works on new generation of new titanium biomaterials and its clinical applications in medicine.
Artur H. Swiergiel
DVM, PhD in Behavioral Pharmacology and Physiology from the University of Cambridge, UK.
Currently Professor of Pharmacology at the Louisiana University Health Sciences Center. Expert in the behavioral and physiological characterization of genetically modified animals and animal models (anxiety, depression, eating disorders, obesity, etc.) The major focus of his work has been on the neurophysiological and molecular mechanisms underlying behavioral disorders. Member of the Board of Directors.
Richard Slomski
Ph.D., Professor of Genetics and Molecular Biology.
Recognized expert on molecular and diagnostic genetics. Executive member of the Polish Academy of Sciences. His area of interest includes molecular diagnostics, molecular basis of inherited diseases, multifactorial genetic disorders and biotechnology. Over the past few years, prepares genetic inserts, which we use for breeding of genetically modified animals, including transgenic rabbits and transgenic pigs. Member of the Board of Directors.
Z.Smorag
Professor of Veterinary Medicine.
Recognized expert in animal reproduction. Over the past ten years, he focused his work on transgenetic animal research. He is currently at the National Institute of Animal Reproduction in Krakow, Poland. Executive Member of the Polish Academy of Sciences. Together with Prof. R.Slomski, works on breeding of genetically modified animals, including transgenic pigs and xenotransplantation project with new applications in medicine. Member of the Board of Directors.